Scholarlink

Purpose <p>This study aimed to report the initial clinical experience with the Saroa™ surgical system (Riverfield Inc., Tokyo, Japan) and to compare perioperative outcomes with the da Vinci surgical system in early-stage lung cancer surgery.</p> Methods <p>A retrospective evaluation was conducted on patients who underwent robotic anatomical lung resection for pathological stage 0–I non-small cell lung cancer (NSCLC) at our institution between July 2023 and May 2025, utilizing either the Saroa or da Vinci® Xi Surgical System. Demographic data, comorbidities, operative variables, complications, and postoperative courses were compared between the groups.</p> Results <p>A total of 60 patients were included in the study (Saroa, n = 30; da Vinci, n = 30). Patients in the Saroa group were older (74.6 vs. 71.2&#xa0;years, p = 0.022). The median operative time (202 vs. 191&#xa0;min, p = 0.524), console time (142 vs. 141.5&#xa0;min, p = 0.505), and blood loss (50 vs. 40&#xa0;mL, p = 0.994) did not differ significantly. The incidence of postoperative complications was similar (23.3% vs. 20.0%, p = 1.000). The median postoperative hospital stay was 7 vs. 8&#xa0;days (p = 0.572).</p> Conclusion <p>Saroa demonstrated feasibility and perioperative safety comparable to that of da Vinci in early stage lung cancer surgery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Initial experience with the Saroa surgical system for early-stage lung cancer: a comparative study with the da Vinci surgical system

  • 期刊论文

  • 发表日期：

    2026年7月21日

查看全文
  • Yuichiro Ueda,
  • Jun-ichi Wakahara,
  • Kensuke Midorikawa,
  • So Miyahara,
  • Hiroyasu Nakashima,
  • Yoshiko Masuda,
  • Takeshi Shiraishi,
  • Toshihiko Sato

摘要

Purpose

This study aimed to report the initial clinical experience with the Saroa™ surgical system (Riverfield Inc., Tokyo, Japan) and to compare perioperative outcomes with the da Vinci surgical system in early-stage lung cancer surgery.

Methods

A retrospective evaluation was conducted on patients who underwent robotic anatomical lung resection for pathological stage 0–I non-small cell lung cancer (NSCLC) at our institution between July 2023 and May 2025, utilizing either the Saroa or da Vinci® Xi Surgical System. Demographic data, comorbidities, operative variables, complications, and postoperative courses were compared between the groups.

Results

A total of 60 patients were included in the study (Saroa, n = 30; da Vinci, n = 30). Patients in the Saroa group were older (74.6 vs. 71.2 years, p = 0.022). The median operative time (202 vs. 191 min, p = 0.524), console time (142 vs. 141.5 min, p = 0.505), and blood loss (50 vs. 40 mL, p = 0.994) did not differ significantly. The incidence of postoperative complications was similar (23.3% vs. 20.0%, p = 1.000). The median postoperative hospital stay was 7 vs. 8 days (p = 0.572).

Conclusion

Saroa demonstrated feasibility and perioperative safety comparable to that of da Vinci in early stage lung cancer surgery.